579
Views
4
CrossRef citations to date
2
Altmetric
Meta-Analysis

Efficacy and Safety of EGFR Inhibitors and Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: a Meta-Analysis

ORCID Icon, , , , , , & show all
Pages 3055-3065 | Received 13 May 2022, Accepted 26 Jul 2022, Published online: 10 Aug 2022
 

Abstract

Aim: To assess the efficacy and safety of EGFR inhibitors combined with (chemo)radiotherapy in unresectable, locally advanced non-small-cell lung cancer. Materials & methods: A systematic review and meta-analysis of prospective trials was performed. Results: Twenty-eight studies of 1640 patients were included. In patients harboring EGFR-sensitive mutations, the pooled objective response rate, 1-year overall survival rate and 1-year progression-free survival rate of EGFR-TKIs + (chemo)radiotherapy were 0.803, 0.766 and 0.554, respectively. Compared with chemoradiotherapy, the addition of EGFR inhibitors did not significantly increase the risk of grade ≥3 pneumonitis and esophagitis. Conclusion: EGFR-tyrosine kinase inhibitors combined with (chemo)radiotherapy are tolerable and the clinical benefit is promising, especially in patients with EGFR-sensitive mutations.

Plain language summary

The aim of this systemic review and meta-analysis was to assess the efficacy and safety of (chemo)radiotherapy combined with therapies targeting EGFR receptor, in unresectable, locally advanced non-small-cell lung cancer. Prospective clinical trials were searched and analyzed, and 28 studies of 1640 patients were included in this analysis. The results showed that the efficacy of (chemo)radiotherapy combined with tyrosine kinase inhibitors targeting EGFR, such as gefitinib and erlotinib, was promising, especially among patients harboring sensitive mutations in EGFR. Besides, this combination therapy was safe, which did not increase the risk of severe pneumonitis and esophagitis. Overall, tyrosine kinase inhibitors targeting EGFR combined with (chemo)radiotherapy are tolerable and the clinical benefit is promising, especially in patients with EGFR-sensitive mutations.

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fon-2022-0491

Author contributions

All authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. X Li: conceptualization, data curation, formal analysis; F Wang: methodology, data curation, formal analysis; H Jia: investigation, writing – original draft; Z Lian: visualization; K Ren: software; Z Yuan: validation; P Wang: writing – review editing; L Zhao: supervision, project administration.

Financial & competing interests disclosure

This study was sponsored by the grant from National Natural Science Foundation of China (no. 81903121). X Li received funding to conduct this research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This study was sponsored by the grant from National Natural Science Foundation of China (no. 81903121). X Li received funding to conduct this research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 104.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 178.00 Add to cart

* Local tax will be added as applicable

Advertisement

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.